Roche's Amylin-Based Weight Loss Drug Delivers 10.7% Reduction in Phase 2 but Falls Short of Eli Lilly's Rival, Sending Zealand Pharma Shares Down 32%
Petrelintide met its primary endpoint with placebo-like tolerability, but a dose ceiling and a seven-point efficacy gap to Lilly's eloralintide raise questions about its standalone future.
4 min read5 sources